GlaxoSmithKline: Autoimmune Diseases trials

The registry lists 29 Autoimmune Diseases studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 18 have results posted.

Phase 1 10Phase 2 2Phase 3 8Phase 4 4No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue DiseaseRecruitingNCT06572384Phase 3
• A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772CompletedNCT03649412Phase 1Results posted
• Phase I Study of GSK2982772 in Japanese Healthy Male ParticipantsCompletedNCT03590613Phase 1Results posted
• A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy SubjectsCompletedNCT03305419Phase 1Results posted
• A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat DosesCompletedNCT03266172Phase 1Results posted
• A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS PtsCompletedNCT02899377Not applicableResults posted
• Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) RegistryCompletedNCT01729455Results posted
• Belimumab Assessment of Safety in SLECompletedNCT01705977Phase 4Results posted
• Belimumab in Remission of VASculitisCompletedNCT01663623Phase 3Results posted
• Efficacy and Safety of Belimumab in Patients With Active Lupus NephritisCompletedNCT01639339Phase 3Results posted
• Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)CompletedNCT01632241Phase 4Results posted
• A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT01597492Phase 4Results posted
• Study of Belimumab Administered Subcutaneously to Healthy SubjectsCompletedNCT01583530Phase 1Results posted
• A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT01484496Phase 3Results posted
• Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)TerminatedNCT00732940Phase 2Results posted
• A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United StatesCompletedNCT00724867Phase 3Results posted
• A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057CompletedNCT00712933Phase 3Results posted
• A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT00424476Phase 3Results posted
• A Study of Belimumab in Subjects With Systemic Lupus ErythematosusCompletedNCT00410384Phase 3Results posted
• A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune DiseaseWithdrawnNCT06413511Phase 1
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT06411249Phase 4
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)WithdrawnNCT03239600Phase 2
• A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic ArthritisWithdrawnNCT02671188Phase 1
• Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy VolunteersCompletedNCT02293161Phase 1
• Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United KingdomCompletedNCT01953822
• Cervarix Long-term Safety SurveillanceCompletedNCT01498627
• A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With AzithromycinCompletedNCT01416350Phase 1
• Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® VaccinationCompletedNCT01153906
• Phase 0 Microdose StudyCompletedNCT00975936Phase 1